<DOC>
	<DOCNO>NCT00006133</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect oral contraceptive contain low-dose synthetic estrogen progestins disease activity premenopausal woman inactive , stable , moderate systemic lupus erythematosus ( SLE ) . II . Determine effect hormone replacement therapy conjugate estrogen progestin disease activity postmenopausal woman inactive , stable , moderate SLE .</brief_summary>
	<brief_title>Randomized Study Oral Contraceptives Hormone Replacement Therapy Women With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age/menopausal status ( 35 under/premenopausal v 50 over/postmenopausal ) . Both strata randomize one two treatment arm . Stratum 1 ( Premenopausal/Oral contraceptive ) : Patients receive either oral ethinyl estradiol norethindrone placebo daily 28 day begin Sunday follow first day menstrual cycle . Stratum 2 ( Postmenopausal/Hormone replacement therapy ) : Patients receive either oral estradiol medroxyprogesterone placebo day 1-12 monthly . Treatment continue arm stratum total 13 course absence severe disease flare-up complication would preclude study participation . All patient follow 1 year .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Established systemic lupus erythematosus meeting American College Rheumatology criterion Inactive disease Systemic Lupus Erythematosus Activity Index ( SLEDAI ) score great 4 No increase score 2 baseline past 3 month Receiving equivalent 5 mg less prednisone per day OR Stable/active disease SLEDAI score 512 No increase score 2 baseline past 3 month Prednisone dose 0.5 mg/kg/day control underlie disease allow stable dose least 3 week No concurrent severe disease activity define follow : Acute renal disease ( i.e. , rise creatinine level , cellular sediment , increase proteinuria ) Involvement 3 organ system require equivalent 0.5 mg/kg/day prednisone Necessity immediate hospitalization symptom control No presence high titer IgG , IgM , IgA antiphospholipid antibody ( aPL ) GPL MPL 40 APL 50 No feature primary antiphospholipid antibody syndrome Prior/Concurrent Therapy Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Prior hysterectomy allow Patient Characteristics Age : 35 oral contraceptive stratum ( premenopausal ) 50 hormone replacement therapy stratum ( postmenopausal ) Menopausal status : Premenopausal oral contraceptive stratum Postmenopausal hormone replacement therapy stratum Folliclestimulating hormone great 40 mIU/mL OR Amenorrhea 6 month Performance status : See Disease Characteristics Hematopoietic : Not specify Hepatic : No hepatic dysfunction No tumor liver Renal : See Disease Characteristics Cardiovascular : No uncontrolled high blood pressure require frequent change medication Concurrent hypertension control stable medication allow No history spontaneous superficial deep venous thrombosis arterial thrombosis No prior myocardial infarction Oral contraceptive stratum : No angina No diastolic blood pressure great 90 mm Hg systolic blood pressure great 140 mm Hg 3 separate determination Hormone replacement therapy stratum : No diastolic blood pressure great 95 mm Hg systolic blood pressure great 145 mm Hg 3 separate determination Pulmonary : No history pulmonary embolus Other : Not pregnant Oral contraceptive stratum : Negative pregnancy test Fertile patient must use effective barrier contraception No prior gynecologic malignancy breast malignancy No undiagnosed vaginal bleeding No diabetes ( present prior use glucocorticoid ) require oral hypoglycemic medication insulin No congenital hyperlipidemia No complicate migraine ( i.e. , associate neurological sequela )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>